These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 33719630)

  • 1. Intracameral r-tPA for the management of severe fibrinous reactions in TASS after cataract surgery.
    Osaadon P; Belfair N; Lavy I; Walter E; Levy J; Tuuminen R; Achiron A; Knyazer B
    Eur J Ophthalmol; 2022 Jan; 32(1):200-204. PubMed ID: 33719630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracameral recombinant tissue plasminogen activator (r-tPA) for refractory toxic anterior segment syndrome.
    Dotan A; Kaiserman I; Kremer I; Ehrlich R; Bahar I
    Br J Ophthalmol; 2014 Feb; 98(2):252-5. PubMed ID: 24276695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intracameral tissue plasminogen activator to treat severe fibrinous effusion after cataract surgery.
    Wedrich A; Menapace R; Ries E; Polzer I
    J Cataract Refract Surg; 1997; 23(6):873-7. PubMed ID: 9292671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of recombinant tissue plasminogen activator for intracameral fibrinolysis following cataract surgery.
    Wedrich A; Menapace R; Mühlbauer-Ries E
    Int Ophthalmol; 1994-1995; 18(5):277-80. PubMed ID: 7607808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracameral tissue plasminogen activator to prevent severe fibrinous effusion after congenital cataract surgery.
    Siatiri H; Beheshtnezhad AH; Asghari H; Siatiri N; Moghimi S; Piri N
    Br J Ophthalmol; 2005 Nov; 89(11):1458-61. PubMed ID: 16234453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intraocular recombinant tissue-plasminogen activator fibrinolysis of fibrin formation after cataract surgery in children.
    Klais CM; Hattenbach LO; Steinkamp GW; Zubcov AA; Kohnen T
    J Cataract Refract Surg; 1999 Mar; 25(3):357-62. PubMed ID: 10079440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy of recombinant tissue plasminogen activator in severe post-operative fibrinous reaction after uneventful phacoemulsification - a case series and review.
    Ibramsah AB; Cheong AI; Wan Muda WN; Ibrahim M
    Rom J Ophthalmol; 2022; 66(1):27-31. PubMed ID: 35531461
    [No Abstract]   [Full Text] [Related]  

  • 8. Tissue plasminogen activator for the treatment of postoperative intraocular fibrinous membranes following cataract surgery.
    Schmitz K; Greite JH; Bartenschlager EM
    Ger J Ophthalmol; 1995 Mar; 4(2):75-9. PubMed ID: 7795512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of immediate postoperative intracameral tissue plasminogen activator (tPA) on anterior chamber fibrin formation in dogs undergoing phacoemulsification.
    Mancuso LA; Nadelstein B; Berdoulay A; Spatola RA
    Vet Ophthalmol; 2019 Jul; 22(4):477-484. PubMed ID: 30773778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of intracameral fibrinous membranes with tissue plasminogen activator.
    Erol N; Ozer A; Topbas S; Yildirim N; Yurdakul S
    Ophthalmic Surg Lasers Imaging; 2003; 34(6):451-6. PubMed ID: 14620747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant tissue plasminogen activator following paediatric cataract surgery.
    Mehta JS; Adams GG
    Br J Ophthalmol; 2000 Sep; 84(9):983-6. PubMed ID: 10966949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant tissue plasminogen activator in cases with fibrin formation after cataract surgery: a prospective randomised multicentre study.
    Heiligenhaus A; Steinmetz B; Lapuente R; Krallmann P; Althaus C; Steinkamp WK; Dick B
    Br J Ophthalmol; 1998 Jul; 82(7):810-5. PubMed ID: 9924378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of postcataract fibrinous membranes with tissue plasminogen activator.
    Moon J; Chung S; Myong Y; Chung S; Park C; Baek N; Rhee S
    Ophthalmology; 1992 Aug; 99(8):1256-9. PubMed ID: 1513579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Tissue plasminogen activator in treatment of fibrinous membranes after cataract surgery].
    Oficjalska-Młyńczak J; Marek J; Zajac-Pytrus H; Nizankowska MH; Koziorowska M
    Klin Oczna; 1996; 98(6):423-5. PubMed ID: 9340414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of total hyphema with relatively low-dose tissue plasminogen activator.
    Kim MH; Koo TH; Sah WJ; Chung SM
    Ophthalmic Surg Lasers; 1998 Sep; 29(9):762-6. PubMed ID: 9760614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Intracameral Tissue Plasminogen Activator During Uveitic Cataract Surgery.
    Hu WF; Etheridge T; Larochelle MB
    Ocul Immunol Inflamm; 2024 Jul; 32(5):673-677. PubMed ID: 37079881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant tissue plasminogen activator (r-TPA) in fibrin dissolution due to postoperative endophthalmitis.
    Riaz Y; Mehta JS; Fernando A; Ferguson V
    Ann Acad Med Singap; 2006 Oct; 35(10):723-5. PubMed ID: 17102897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of Anterior Segment OCT in the Management of Uveitic Cataract Surgery: A Fibrinoid Syndrome Case Treated with rtPA.
    Muñoz-Solano J; Tondini G; Zicarelli F; Staurenghi G; Oldani M; Invernizzi A
    Ocul Immunol Inflamm; 2024 Aug; 32(6):1128-1131. PubMed ID: 37140351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic application of tissue plasminogen activator for fibrin reaction after cataract surgery.
    Ozveren F; Eltutar K
    J Cataract Refract Surg; 2004 Aug; 30(8):1727-31. PubMed ID: 15313298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapeutic and prophylactic application of TPA (recombinant tissue plasminogen activator) into the anterior chamber of the eye].
    Rehfeldt K; Höh H
    Ophthalmologe; 1999 Sep; 96(9):587-93. PubMed ID: 10501987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.